Interim protocol on dispensing of adrenaline auto-injectors, 150microgram – NHS England

This guidance on the dispensing of adrenaline auto-injectors (150microgram) has been developed for pharmacies and dispensing GP practices. This validation protocol has been developed to ensure consistent practice nationally and to prevent the need for any local re-interpretation.

Standards of proficiency for nursing associates – Nursing and Midwifery Council

The standards of proficiency presented here represent the standards of knowledge and skills that a nursing associate will need to meet in order to be considered by the NMC as capable of safe and effective nursing associate practice. These standards

Guidelines for Health & Justice Clinical Reviewers – NHS England

This document provides NHS England Health & Justice Commissioning Teams and Clinical Reviewers with national operating procedures and guidelines for the provision of Clinical Review reports to the Prisons and Probation Ombudsman (PPO).  

Guidelines for Health & Justice Clinical Reviewers – NHS England

This document provides NHS England Health & Justice Commissioning Teams and Clinical Reviewers with national operating procedures and guidelines for the provision of Clinical Review reports to the Prisons and Probation Ombudsman (PPO).  

Renal replacement therapy and conservative management: NICE guideline [NG107] – NICE

This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating

Decision-making and mental capacity: NICE guideline [NG108] – NICE

This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity

Cabozantinib for untreated advanced renal cell carcinoma: Technology appraisal guidance [TA542] – NICE

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA543] – NICE

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends:  Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as

Cardiac arrhythmias in coronary heart disease: SIGN 152 – Scottish Intercollegiate Guidelines Network

This guideline provides evidence-based recommendations for the management of cardiac arrest and the arrhythmias associated with acute coronary syndrome (ACS), chronic CHD and cardiac surgery. It excludes arrhythmias not associated with CHD such as supraventricular tachycardias associated with accessory pathways

iFuse for treating chronic sacroiliac joint pain: Medical technologies guidance [MTG39] – NICE

Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain. The case for adopting the iFuse implant system to treat chronic sacroiliac joint pain is supported by the evidence. Using iFuse leads to improved pain relief, better quality of life

myAIRVO2 for the treatment of chronic obstructive pulmonary disease: Medtech innovation briefing [MIB161] – NICE

NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease. The technology described in this briefing is myAIRVO2. It is designed to warm and humidify respiratory gases used for nasal high-flow therapy. This briefing

E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta: Medical technologies guidance [MTG16] – NICE

Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta. This guidance has been updated to include a review of the cost model using more recent values. New evidence and updated costs identified

OxyMask for delivering oxygen therapy: Medtech innovation briefing [MIB160] – NICE

NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy. The technology described in this briefing is OxyMask. It is used for delivering oxygen therapy. The innovative aspect is the novel design, which is intended to improve the efficiency and

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628] – NICE

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder. This guidance replaces NICE interventional procedures guidance on intravesical microwave

Asthma: Quality standard [QS25] – NICE

This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement. In September 2018, this quality standard was updated in response to an annual review, which identified

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia: Interventional procedures guidance [IPG629] – NICE

Evidence-based recommendations on transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves injecting a high-speed jet of water into the prostate to destroy some of the tissue. The evidence on transurethral

Eating disorders: Quality standard [QS175] – NICE

This quality standard covers assessment, treatment, monitoring and care for children, young people and adults with an eating disorder. It describes high-quality care in priority areas for improvement.

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Emergency and acute medical care in over 16s: Quality standard [QS174] – NICE

This quality standard covers the organisation and delivery of emergency and acute medical care in the community and in hospital. It covers adults (16 and over) who seek, or are referred for, emergency NHS care for a suspected or confirmed

Preventing suicide in community and custodial settings: NICE guideline [NG105] – NICE

This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to: help local services work more effectively together to prevent suicide identify and help people at risk prevent suicide in places where it